

JAN. 9. 2006 3:03PM

AVENTIS US PAT DEPT

RECEIVED
CENTRAL FAX CENTER

JAN 09 2006

NO. 1027 P. 3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

SCHWINK, et. al.

Examiner: DENTZ, Bernard I.

Art Unit: 1625

Application No.: 10/779,853

Filed: February 17, 2004

Title: **SUBSTITUTED N-ARYL HETEROCYCLES,
PROCESS FOR THEIR PREPARATION AND
THEIR USE AS MEDICAMENTS**

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for
Patents, Alexandria, VA 22313, on

January 9, 2006
Date of Transmission

Brian Pritchett
Signature


RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

This paper is responsive to the Restriction Requirement mailed on 11/07/05. Applicant expressly reserves the right to traverse the Restriction upon further communication from the USPTO regarding the number and characterization of Groups that the Examiner believes are patentably distinct.


Per Examiner's request, Applicant herein elects the species that is Example 1. This species has the following formula:



Furthermore, Applicant elects the method of treating obesity (Claim 11) with a compound of Claim

1. Support for this method can be found on page 1, line 22 of the specification and elsewhere throughout the specification.

Respectfully submitted,



Barbara E. Kurys, Reg. No. 34,650
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
(a member of the sanofi-aventis group)
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2965
Telefax (908) 231-2626

Aventis Docket No. DEAV2003/0011 US NP